Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

Published:2024-08 Issue:8 Volume:123 Page:875-881
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Shih Jin-Yuan^ORCID,Luo Yung-Hung^ORCID,Chang Gee-Chen,Chang John Wen-Cheng,Wang Chin-Chou,Yang Tsung-Ying^ORCID,Fang Wei-Tse,Shau Wen-Yi

Funder

Pfizer

Publisher

Elsevier BV

Reference17 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer;Kwak;N Engl J Med,2010

3. Later-line treatment with lorlatinib in ALK- and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis;Hochmair;Pharmaceuticals,2020

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

5. Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer;Camidge;N Engl J Med,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pragmatic guide for management of adverse events associated with lorlatinib;Lung Cancer;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP